Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study - Emery, P; Bingham, C O; Burmester, G R; Bykerk, V P; Furst, D E; Mariette, X; van der Heijde, D; van Vollenhoven, R; Arendt, C; Mountian, I; Purcaru, O; Tatla, D; et al. (Annals of the rheumatic diseases, 2017)
Keywords: Adult; Analysis of covariance; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - diagnostic imaging; Arthritis, Rheumatoid - drug therapy; Certolizumab Pegol - adverse effects; Certolizumab Pegol - therapeutic use; Clinical and Epidemiological Research; Double-Blind Method; Drug Therapy, Combination - adverse effects; Female; Humans; Hypothesis testing; Infections - chemically induced; Male; Methotrexate - administration & dosage; Methotrexate - adverse effects; Methotrexate - therapeutic use; Middle Aged; Patients; Prognosis; Radiography; Remission (Medicine); Remission Induction; Rheumatoid arthritis; Tuberculosis; Anti-TNF; DMARDs (biologic); Methotrexate; Early Rheumatoid Arthritis